JP2016528174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528174A5 JP2016528174A5 JP2016517040A JP2016517040A JP2016528174A5 JP 2016528174 A5 JP2016528174 A5 JP 2016528174A5 JP 2016517040 A JP2016517040 A JP 2016517040A JP 2016517040 A JP2016517040 A JP 2016517040A JP 2016528174 A5 JP2016528174 A5 JP 2016528174A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- cdp
- conjugate
- jak inhibitor
- jak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 description 37
- 238000000034 method Methods 0.000 description 17
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000004012 Tofacitinib Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 229960001350 tofacitinib Drugs 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- -1 restaurtinib Chemical compound 0.000 description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000000743 hydrocarbylene group Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229950008814 momelotinib Drugs 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical group C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- ASUGUQWIHMTFJL-QGZVFWFLSA-N (2r)-2-methyl-2-[[2-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- DVCPYUTZIIXGFE-UHFFFAOYSA-N 649nj54i9p Chemical compound ClC1=CC=CC(Cl)=C1C1=NC(C2=CC=CN=C2NC2=CN=CC=C22)=C2N1 DVCPYUTZIIXGFE-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- JCINBYQJBYJGDM-UHFFFAOYSA-N bms-911543 Chemical compound CCN1C(C(=O)N(C2CC2)C2CC2)=CC(C=2N(C)C=NC=22)=C1N=C2NC=1C=C(C)N(C)N=1 JCINBYQJBYJGDM-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- MPYACSQFXVMWNO-UHFFFAOYSA-N n-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1C(C)(C)CN1C(=O)C1=CC=C(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)C=C1 MPYACSQFXVMWNO-UHFFFAOYSA-N 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829797P | 2013-05-31 | 2013-05-31 | |
| US61/829,797 | 2013-05-31 | ||
| PCT/US2014/040230 WO2014194195A2 (en) | 2013-05-31 | 2014-05-30 | Cyclodextrin-based polymers for the therapeutic delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528174A JP2016528174A (ja) | 2016-09-15 |
| JP2016528174A5 true JP2016528174A5 (OSRAM) | 2017-07-13 |
Family
ID=51985801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517040A Pending JP2016528174A (ja) | 2013-05-31 | 2014-05-30 | 治療的送達用のシクロデキストリンベースのポリマー |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20140357557A1 (OSRAM) |
| JP (1) | JP2016528174A (OSRAM) |
| AU (1) | AU2014273983A1 (OSRAM) |
| CA (1) | CA2913752A1 (OSRAM) |
| WO (1) | WO2014194195A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105924444B (zh) * | 2015-03-11 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | Jak抑制剂的晶型及其制备方法 |
| CN104987333B (zh) * | 2015-07-14 | 2017-01-11 | 苏州富士莱医药股份有限公司 | 一种Filgotinib的合成方法 |
| ES2973564T3 (es) * | 2015-09-28 | 2024-06-20 | Cti Biopharma Corp | Tratamiento o prevención de enfermedad de injerto contra huésped |
| US20180311268A1 (en) * | 2015-10-20 | 2018-11-01 | Emory University | Response-guided hcv therapy |
| HUE049775T2 (hu) * | 2015-11-24 | 2020-10-28 | Theravance Biopharma R&D Ip Llc | Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei |
| WO2017177055A1 (en) * | 2016-04-08 | 2017-10-12 | Liang Zhao | Cyclodextrin-based polymers for therapeutic delivery |
| CN110072519A (zh) * | 2016-12-14 | 2019-07-30 | 普罗根尼蒂公司 | 使用jak抑制剂治疗胃肠道疾病及装置 |
| US10472366B2 (en) | 2017-03-08 | 2019-11-12 | Theravance Biopharma R&D Ip, Llc | Glucuronide prodrugs of tofacitinib |
| JP7280193B2 (ja) * | 2017-03-16 | 2023-05-23 | ブレイズ バイオサイエンス， インコーポレイテッド | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 |
| US10745405B2 (en) | 2017-05-23 | 2020-08-18 | Theravance Biopharma R&D Ip, Llc | Glucuronide prodrugs of Janus kinase inhibitors |
| CN110662755A (zh) * | 2017-05-23 | 2020-01-07 | 施万生物制药研发Ip有限责任公司 | 托法替尼的硫代氨基甲酸酯前药 |
| CA3081802A1 (en) | 2017-11-03 | 2019-05-09 | Osteoanalgesia, Llc | Drug delivery system for treating disease |
| US20210015933A1 (en) * | 2018-03-30 | 2021-01-21 | Seikagaku Corporation | Bioactive carboxylic acid type compound-polymer conjugate, and method for manufacturing the same |
| US10912759B2 (en) * | 2018-05-17 | 2021-02-09 | William Andrew Clark | Topical gel compositions for the treatment of Staphylococcal infections |
| CN111094314B (zh) * | 2018-08-15 | 2022-08-12 | 江苏豪森药业集团有限公司 | 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| CN110403944A (zh) * | 2019-08-07 | 2019-11-05 | 中南大学湘雅医院 | Decernotinib在制备治疗银屑病的外用药物中的应用、药物及制备方法 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| EP4357346A4 (en) * | 2021-07-20 | 2025-06-11 | Coval Biopharma (Shanghai) Co., Ltd. | EXTERNAL ANTI-INFLAMMATORY AGENT COUPLING A COMPOUND AND A DRUG, PREPARATION METHOD THEREFOR AND USE THEREOF |
| WO2023039213A1 (en) * | 2021-09-09 | 2023-03-16 | Biora Therapeutics, Inc. | Aqueous formulations of tofacitinib and tofacitinib salts |
| KR20240150493A (ko) * | 2022-02-21 | 2024-10-15 | 온퀄리티 파마슈티컬스 차이나 리미티드 | 화합물 및 그 용도 |
| CA3259413A1 (en) * | 2022-06-13 | 2023-12-21 | The University Of Queensland | USES OF JAK INHIBITORS IN THE MANAGEMENT OF DEPRESSION AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES ASSOCIATED WITH INFLAMMATION |
| WO2025040148A1 (zh) * | 2023-08-22 | 2025-02-27 | 北京普祺医药科技股份有限公司 | 一种用于jak抑制剂的外用凝胶及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007098611A1 (en) * | 2006-03-03 | 2007-09-07 | Queen's University At Kingston | Compositions for treatment of cancer |
| CA2781669A1 (en) * | 2009-11-23 | 2011-05-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| WO2012003457A1 (en) * | 2010-07-01 | 2012-01-05 | Mtm Research Llc | Anti-fibroblastic fluorochemical emulsion therapies |
| US20120213854A1 (en) * | 2010-09-30 | 2012-08-23 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
| EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
-
2014
- 2014-05-30 CA CA2913752A patent/CA2913752A1/en not_active Abandoned
- 2014-05-30 WO PCT/US2014/040230 patent/WO2014194195A2/en not_active Ceased
- 2014-05-30 US US14/291,745 patent/US20140357557A1/en not_active Abandoned
- 2014-05-30 JP JP2016517040A patent/JP2016528174A/ja active Pending
- 2014-05-30 AU AU2014273983A patent/AU2014273983A1/en not_active Abandoned
-
2017
- 2017-07-11 US US15/646,584 patent/US20180117168A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528174A5 (OSRAM) | ||
| Birke et al. | Polypeptoid-block-polypeptide copolymers: Synthesis, characterization, and application of amphiphilic block copolypept (o) ides in drug formulations and miniemulsion techniques | |
| Shukla et al. | The impact of aspect ratio on the biodistribution and tumor homing of rigid soft‐matter nanorods | |
| Moore et al. | Multifunctional Polymer‐Coated Carbon Nanotubes for Safe Drug Delivery | |
| JP2016153410A5 (OSRAM) | ||
| JP2017511322A5 (OSRAM) | ||
| JP2015528002A5 (OSRAM) | ||
| JP2014531476A5 (OSRAM) | ||
| JP2017505104A5 (OSRAM) | ||
| JP2015532295A5 (OSRAM) | ||
| JP2011523643A5 (OSRAM) | ||
| JP2011530597A5 (OSRAM) | ||
| JP2019512478A5 (OSRAM) | ||
| JP2019512006A5 (OSRAM) | ||
| JP2019523761A5 (OSRAM) | ||
| JP2001514167A5 (OSRAM) | ||
| JP2010513441A5 (OSRAM) | ||
| JP2020519676A5 (OSRAM) | ||
| US20220054659A1 (en) | Psma-targeted pamam dendrimers for specific delivery of imaging, contrast and therapeutic agents | |
| CN108601952B (zh) | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 | |
| CN102174579B (zh) | 可还原降解的梳型高分子基因载体及其制备方法 | |
| JP2009536246A5 (OSRAM) | ||
| JP2011506296A5 (OSRAM) | ||
| RU2018128032A (ru) | Полимеры на основе циклодекстрина, способы, композиции и применение | |
| JP2014530882A5 (OSRAM) |